Eyeworld

60 | EYEWORLD | SEPTEMBER 2021 R YES CONNECT EFRACTIVE by Liz Hillman Editorial Co-Director About the physicians Eric Donnenfeld, MD Ophthalmic Consultants of Long Island Garden City, New York Blake Williamson, MD Williamson Eye Center Baton Rouge, Louisiana Elizabeth Yeu, MD Virginia Eye Consultants Virginia Beach, Virginia one who is, from the perspective of an optic and arm's length, less than 6'10"," she quipped. Another benefit of PanOptix, Dr. Yeu con- tinued, is its platform. While the lens is AcrySof material, it's based on its own new platform, which uses 88% of light, half of which is di- rected toward distance. "It has incredible light utilization," Dr. Yeu said. She said that for a light-splitting technolo- gy, the concerns over contrast sensitivity are less than observed in the clinical trial. You still have to respect the patient selec- tion rules as you normally would for multifo- cality, she noted, which include a stable ocular surface and no other intraocular pathology. "If those rules are observed, it works ex- tremely well in patients," Dr. Yeu said. The addition of Vivity (Alcon), a non-dif- fractive EDOF, to the market earlier this year, Dr. Yeu said, has expanded who she is comfortable offering PanOptix to. Here's how: She has been mixing and matching Vivity and PanOptix for patients who are very concerned with the night dysphotopsia profile of the trifocal. Patients Improvements in presbyopia- correcting IOLs continue continued on page 62 Curing presbyopia is still the "holy grail" of anterior segment surgery. While there have been incredible steps forward in the last 3 decades, we are still left with much to desire out of the current technologies. Recent advancements from many companies have me excited for the future. We are slowly achieving true spectacle independence. This article will highlight new technologies that I know have a bright future and potential to truly shape presbyopia therapy. I think if these technologies do as they say, we will finally see a shift in the presbyopia market share. —Michael Patterson, DO YES Connect Co-Editor T here has been a lot of movement in the presbyopia-correcting IOL space. In the July issue of EyeWorld, the YES Connect column took a look at "ring- less" extended depth of focus (EDOF) technologies. This column moves the conver- sation forward along the presbyopia-correction spectrum, examining trifocal, combined multi- focal-EDOF, and accommodating technology on the horizon. Trifocals The AcrySof IQ PanOptix (Alcon) became the first trifocal approved for use in the U.S. in August 2019. In the 2 years post-approval, surgeons who have adopted it, like Elizabeth Yeu, MD, have become familiar with its pros and cons. Dr. Yeu was part of the FDA pivotal trial for PanOptix and said that of the multifocal IOL op- tions, it's what she uses most frequently in her practice when patients desire spectacle indepen- dence and are good candidates. Prior to PanOptix, Dr. Yeu said there was a significant gap at intermediate vision in mul- tifocal IOL technology. Surgeons mixed and matched IOLs to try to accommodate for this, or patients had to move their arms in and out to try to find the sweet spot. PanOptix, Dr. Yeu said, reduced her need to mix and match IOLs. Its near sweet spot at –2.5 D or 40 cm and inter- mediate at –1.5 or 60 cm, coupled with distance vision, provides "the most ideal range for any- Dr. Williamson implants the first Synergy in Louisiana. Source: Blake Williamson, MD

• Blank Page
• Blank Page (1)